In adults with obesity, bimagrumab maintains or slightly increases muscle mass while reducing fat, whereas semaglutide reduces muscle mass by 7.4% while reducing fat over 72 weeks.
See the scientific wording
In adults with obesity, treatment with bimagrumab (30 mg/kg IV every 12 weeks) preserves or slightly increases lean mass over 72 weeks, while treatment with semaglutide (2.4 mg SC weekly) results in a 7.4% reduction in lean mass over the same period, indicating that bimagrumab uncouples fat loss from muscle loss.
Very strong evidence
Randomized trialsOne high-quality study supports this claim.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2026
Semaglutide helps people lose weight but also makes them lose muscle. When bimagrumab is added, people still lose a lot of fat, but they keep most of their muscle. So bimagrumab helps protect muscle while losing fat.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Bimagrumab blocks specific receptors on muscle and fat cells, causing muscle to build more protein and fat to break down more fat. When a person loses weight, this keeps muscle from breaking down while still allowing fat to be lost.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In adults with obesity, bimagrumab maintains or slightly increases muscle mass while reducing fat, whereas semaglutide reduces muscle mass by 7.4% while reducing fat over 72 weeks.
Mechanism
1 studyBimagrumab stops signals that limit muscle growth and promote fat storage, so muscle stays strong while fat breaks down. When calories are reduced, the body burns fat instead of muscle because the muscle-building signals are still active.
Bimagrumab blocks specific receptors on muscle and fat cells, causing muscle to build more protein and fat to break down more fat. When a person loses weight, this keeps muscle from breaking down while still allowing fat to be lost.
Bimagrumab binds to activin type II receptors on skeletal muscle and adipose tissue cells
Inhibition of myostatin and activin A signaling through the ActRII-ALK4 pathway in skeletal muscle increases protein synthesis and reduces muscle breakdown
Inhibition of activin signaling through the ActRII-ALK7 pathway in adipose tissue increases lipolysis and lipid mobilization
Reduced caloric intake from semaglutide creates a systemic energy deficit that drives fat mobilization without triggering muscle catabolism due to concurrent anabolic signaling in muscle
Net effect is preservation or slight increase in lean mass alongside significant reduction in fat mass
Evidence from Studies
Supporting (1)
Community contributions welcome
Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
Semaglutide helps people lose weight but also makes them lose muscle. When bimagrumab is added, people still lose a lot of fat, but they keep most of their muscle. So bimagrumab helps protect muscle while losing fat.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Bimagrumab vs Semaglutide on Lean Mass Changes in Obesity Over 72 Weeks
Population: Adults with obesity; Intervention: Bimagrumab 30 mg/kg IV every 12 weeks; Comparator: Semaglutide 2.4 mg SC weekly; Outcome: Change in lean mass measured by DXA at 72 weeks; Duration: 72 weeks.
Double-Blind, Placebo-Controlled Trial Comparing Bimagrumab and Semaglutide on Lean Mass in Obesity Over 72 Weeks
Population: Adults with obesity; Intervention: Bimagrumab 30 mg/kg IV every 12 weeks; Comparator: Semaglutide 2.4 mg SC weekly; Outcome: Change in lean mass via DXA at 72 weeks; Duration: 72 weeks; Design: Randomized, double-blind, parallel-group.
Prospective Cohort Study of Lean Mass Trajectories in Obese Adults Treated with Bimagrumab or Semaglutide Over 72 Weeks
Population: Adults with obesity initiating bimagrumab or semaglutide; Intervention: Real-world dosing of bimagrumab or semaglutide; Comparator: No concurrent intervention; Outcome: Lean mass change measured by DXA at 72 weeks; Duration: 72 weeks.
Case-Control Study of Severe Lean Mass Loss in Obese Adults Treated with Semaglutide vs. Bimagrumab
Population: Obese adults with >5% lean mass loss (cases) vs. those with <1% change (controls); Exposure: Prior use of semaglutide or bimagrumab over 72 weeks; Outcome: Drug exposure history; Duration: Retrospective 72-week window.
In Vitro Analysis of Bimagrumab and Semaglutide Effects on Human Skeletal Muscle Cell Protein Turnover
Population: Human skeletal muscle myotubes; Intervention: Exposure to bimagrumab (30 mg/kg equivalent) or semaglutide (2.4 mg/week equivalent); Comparator: Vehicle control; Outcome: Myofibrillar protein synthesis and degradation rates; Duration: 72 hours.